Nasopharyngeal carcinoma (NPC) remains a challenging head and neck malignancy, particularly in its recurrent or metastatic forms. Despite initial treatment with radiotherapy, chemotherapy, and immune checkpoint inhibitors—most commonly PD-1/PD-L1 inhibitors—many patients experience disease progression with limited therapeutic options remaining. In a significant advancement for this patient population, China’s National Medical Products Administration (NMPA) has recently approved Weibeketuo Tab Monoclonal Antibody for Injection (brand name: Meiyuheng), a novel, domestically developed epidermal growth factor receptor (EGFR)-targeting antibody–drug conjugate (ADC), for use in adults with recurrent or metastatic NPC.
Meiyuheng is indicated specifically for adult patients whose disease has progressed after at least two prior lines of systemic therapy—including platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. It is not intended for patients with newly diagnosed, early-stage NPC, nor for those who have received only first-line treatment or have never been exposed to immunotherapy. Clinical evidence supporting its approval comes from a multicenter, single-arm Phase IIa trial evaluating MRG003—the investigational name for this ADC—in patients with recurrent or metastatic NPC who had progressed following ≥1 line of platinum-containing chemotherapy, with or without prior PD-1/PD-L1 inhibition. Results demonstrated clinically meaningful antitumor activity and a manageable safety profile across two dose cohorts (2.0 mg/kg and 2.3 mg/kg).
The mechanism of action reflects contemporary ADC design principles. Meiyuheng consists of a humanized anti-EGFR monoclonal antibody covalently linked via a valine–citrulline cleavable linker to monomethyl auristatin E (MMAE), a potent microtubule-disrupting cytotoxic agent. Upon binding to EGFR—overexpressed on the surface of many NPC tumor cells—the conjugate undergoes receptor-mediated internalization and lysosomal degradation, releasing MMAE intracellularly to induce mitotic arrest and apoptosis. This targeted delivery aims to maximize tumor cell killing while minimizing off-target toxicity.
While Meiyuheng represents a promising new option for heavily pretreated patients, comprehensive supportive care remains essential. Patients undergoing treatment—especially those with prior radiation exposure—should prioritize oral and nasopharyngeal hygiene, including frequent saline rinses and nasal irrigation. Skin protection from sun exposure and meticulous mucosal moisturization are critical. Nutritionally, diets should emphasize high-quality protein, hydration, and antioxidant-rich fruits and vegetables, while avoiding irritants such as spicy, smoked, or excessively hot foods—and strictly abstaining from tobacco and alcohol. Regular, low-intensity physical activity, consistent sleep hygiene, and psychosocial support—including family engagement and professional counseling—help mitigate treatment-related fatigue and anxiety. Close monitoring is mandatory: routine blood counts, contrast-enhanced imaging, and nasopharyngoscopy enable early detection of complications such as worsening mucositis, dermatologic toxicity, or unexpected bleeding—all warranting prompt clinical evaluation.
In summary, Meiyuheng offers a biologically rational, precision oncology approach for patients with recurrent or metastatic NPC who have exhausted standard therapies. Its NMPA approval marks a milestone in the evolving treatment landscape for this historically difficult-to-treat cancer—providing not only a statistically and clinically significant survival benefit but also a tangible improvement in quality of life for individuals facing advanced disease.